TNIP1基因rs10036748 TT基因型与中国银屑病患者甲氨蝶呤疗效更好相关:一项前瞻性队列研究
该前瞻性队列研究纳入221例银屑病患者,评估临床因素及银屑病易感基因变异与甲氨蝶呤(MTX)疗效的关联。结果显示,TNIP1基因rs10036748 TT基因型与第12周PASI 75应答显著相关,且PASI 90应答率更高;低BMI、无关节炎及该基因型是MTX良好应答的独立相关因素。
要点
- 低BMI、无关节炎及rs10036748 TT基因型与MTX良好应答独立相关。
核心结论
- TNIP1基因rs10036748 TT基因型、较低BMI及无关节炎的银屑病患者对甲氨蝶呤应答更好。
研究设计与样本
- 前瞻性队列研究,共纳入221例银屑病患者,筛选阶段90例,验证阶段全部221例。
主要发现
- 筛选阶段49%、验证阶段45%的患者达到PASI 75改善。
- 银屑病合并关节炎和高BMI对MTX疗效有负面影响。
关键数值与推荐
- 应答者定义为第12周PASI改善≥75%,无应答者定义为PASI改善<50%。
临床怎么用
- 对于低BMI、无关节炎且携带TNIP1 rs10036748 TT基因型的银屑病患者,可预期更好的MTX应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methotrexate (MTX) is an efficacious treatment for psoriasis; however, its widespread application is limited by its unpredictable efficacy. OBJECTIVES: To investigate the association of clinical factors and variants of psoriasis susceptibility genes with clinical responses to MTX in a prospective cohort. METHODS: A total of 221 patients with psoriasis were recruited. Patients who achieved Psoriasis Area and Severity Index (PASI) improvement ≥ 75% at week 12 were defined as responders, whereas those with PASI improvement < 50% were defined as nonresponders. In 90 screening patients, genetic variants for 18 single-nucleotide polymorphisms in 14 susceptibility genes, and HLA-Cw6 status were initially compared for responders and nonresponders. Statistically significant associations in genetic variants were verified in all 221 patients. RESULTS: Overall, 49% and 45% of patients achieved PASI 75 improvement during screening and verification stages, respectively. Concomitant arthritis with psoriasis and high body mass index (BMI) negatively affect the efficacy of MTX. TT genotype of rs10036748 in TNIP1 was significantly associated with PASI 75 response at week 12 (54% and 37%, P < 0·05). A significantly higher PASI 90 response was observed in patients with TT genotype of rs10036748 (27% vs. 12%, P < 0·01) and TC/TT genotype of rs4112788 in LCE3D (25% vs. 13%, P < 0·05) at week 12 compared with those who had other genotypes. After adjustment for all confounding factors, only BMI (P < 0·05), arthritis (P < 0·05) and genotype of rs10036748 (P < 0·05) were significantly associated with clinical responses to MTX. CONCLUSIONS: Patients with psoriasis with TT genotype of rs10036748 in TNIP1, with lower BMI, without arthritis will achieve a better response to MTX.
引用
- Yan KX, Zhang YJ, Han L, et al. TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study. Br J Dermatol. 2019. PMID: 31020648. doi:10.1111/bjd.17704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。